




**Supplemental Figure 1. A.** Expression of T and NK cell activation markers and immune checkpoints by metastatic site. **B.** Gene expression profiles of B cells and plasma cells across all samples. **C.** Heatmap showing B cell and plasma cell markers across metastatic sites.




**Supplemental Figure 2. A.** Expression of myeloid cell markers by metastatic site. **B.** Gene expression associated with classical and alternative macrophage activation in all macrophages by site of metastasis. **C.** Gene expression associated with classical and alternative macrophage activation in nine individual macrophage subpopulations by site of metastasis (top). Distribution of macrophage subpopulations by total cell counts of individual sub-clusters across metastatic sites (bottom). **D.** Pie charts show macrophage composition by metastatic site. Colored halo indicates predicted activation program of each macrophage sub-cluster based on gene expression profiles specific to respective metastatic site.



**Supplemental Figure 3. A.** Snapshots of each control sample from patients without metastasis to the central nervous system, with pie charts showing the cellular landscape for T cells (left pie chart) and myeloid cells (right pie chart). Halo indicates predicted behavior of each cell sub-cluster (e.g. inactive, activated, proliferating, naïve and immune suppressive). Bar graph shows percent of tumor made up of tumor cells, plasma, B cells, myeloid cells and CD4+ or CD8+ T cells. B-E. Treatment timeline of two poor responders, with accompanying cellular landscape information as panel A, showing much greater proportion of T cell compartment to be comprised of inactive T cell sub-classes and a greater portion of the myeloid cell compartment to be comprised of immune-suppressive cell sub-classes than the exceptional responder in Figure 4D.




**Supplemental Figure 4. A.** Cell type distribution of brain metastasis samples treated with targeted therapy or immunotherapy, breakdown by major lymphocytic and myeloid cell types, normalized to every 100 cells analyzed. **B**. Detailed breakdown of cell phenotypes for T/NK cells, myeloid cells and other cells. Halo indicates predicted behavior of each cell sub-cluster (e.g. inactive, activated, proliferating, naïve and immune suppressive).




**Supplemental Figure 5.** Heatmap showing relative expression of MHC class I and II molecules on melanoma cells from samples with and without DC3 present.




Receptor (DC3)- Ligand (T cell)




**Supplemental Figure 6. Cell-cell interaction analysis using SingleCellSignalR.** Heatmap visualizing the interactions with LRscore higher than 0.5 between DC3 and CD4 or CD8 subpopulations, further filtered by DC3-specific markers. The interaction score is a product of the number of all interactions with LRscore higher than 0.5 and the sum of these interactions' LR scores.



**Supplemental Figure 7.** Multiplex-IF staining for DC3 cells using DAPI (blue), LAMP3 (green), CCL19 (cyan) and IDO1 (yellow). Representative image showing detection of a DC3 cell in MB-15 sample.




**Supplemental Figure 8.** Validation analysis of samples from melanoma metastases in a publicly available validation dataset (Tirosh et al, 2016). **A.** Unsupervised clustering identified the 25 myeloid cell clusters. **B.** Unsupervised clustering identifies 9 subsets of T cells and 1 cluster of NK cells.





Α






**Supplemental Figure 9. A.** t-SNE plot showing the distribution of myeloid cells in melanoma samples from a publicly available validation dataset (Tirosh et al, 2016). The DC3 cells are highlighted in larger brown circles. **B.** Expression of key markers that distinguish the major subsets of myeloid cells, including DC3, in validation dataset.






## В


	PC1	PC2	PC3	PC4
CCL19	0.49	-0.54	-0.66	0.20
IDO1	0.50	0.59	0.07	0.62
IDO2	0.52	0.37	-0.14	-0.76
LAMP3	0.49	-0.47	0.73	-0.03



**Supplemental Figure 10. A.** Correlation of DC3 gene signature in TCGA. **B.** PC loading for DC3 gene signature in TCGA. **C.** Correlation of DC3 gene signature in Moffitt Cohort (N=135).



**Supplemental Figure 11.** Overall survival for melanoma patients with LMM metastases whose CSF samples contained high DC3 cells vs. low DC3 cells (cut point 0.45).



**Supplemental Figure 12. A.** Correlation of individual genes from the DC3 gene signature to overall survival in TCGA dataset. **B.** Univariate cox proportional-hazards models for individual genes from the cDC3 gene signature in TCGA dataset.